Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients

This study looks at the best dose of a drug called brentuximab vedotin for patients with two types of rare skin lymphomas — mycosis fungoides and Sézary syndrome — that have not responded well to previous treatments. **You may be eligible if...** - You have been diagnosed with mycosis fungoides or Sézary syndrome confirmed by biopsy at the enrolling institution - Your disease is at stage IB or higher (patches or plaques covering 10% or more of skin, or more advanced) - You are 18 years of age or older - Your performance status (ability to carry out daily activities) is rated 0–2 on the standard medical scale - For Cohort 1: you have NOT previously received brentuximab vedotin - For Cohort 2: you HAVE previously received brentuximab vedotin for this condition **You may NOT be eligible if...** - You have a less advanced disease stage (below stage IB) - You do not meet the performance status requirements Talk to your doctor to see if this trial is right for you.